Zealand Pharma Strengthens Leadership with New Hire from Eli Lilly as Obesity Pipeline Expands
In a strategic move signaling its commitment to tackling obesity through innovative therapies, Zealand Pharma has announced the appointment of a former Eli Lilly executive, Chris Pashley. This transition comes as the biotech firm accelerates its efforts in developing treatments aimed at obesity, a growing global health concern.
Continue reading
Lilly's New Weight-loss Pill Rivals Ozempic, Leading to Surge in Stock Prices
In a significant development within the pharmaceutical market, shares of Eli Lilly surged following the announcement of promising results for its new weight-loss medication, believed to be on par with the well-established Ozempic. This news has generated considerable enthusiasm amongst investors and healthcare professionals alike, with the potential to reshape the competitive landscape of weight-loss therapies.
Continue reading
Lilly's Stock Takes a Hit Following Trump's Withdrawal of Medicare Obesity Treatment Proposal
In a surprising turn of events, shares of pharmaceutical giant Eli Lilly experienced a notable decline after former President Donald Trump announced that he would not be proceeding with a proposal to include obesity treatments under Medicare coverage. This unexpected withdrawal has sent ripples through the investor community, raising concerns about the potential impact on Lilly's lucrative weight-loss medications.
Continue reading
Hims Teams Up with Eli Lilly to Offer Zepbound Through Telehealth Services
In a significant development within the telehealth industry, Hims, a leading healthcare company focused on providing convenient access to prescription medications and wellness products, announced that it will begin selling Eli Lilly’s weight-loss drug, Zepbound, through its online platform. This strategic partnership marks a pivotal moment for both companies as they seek to expand their reach in the weight management market.
Continue reading
Eli Lilly's Kisunla Misses Out on EU Approval for Alzheimer's Treatment
In a significant setback for Eli Lilly and Company, the European Medicines Agency (EMA) has decided not to recommend the marketing authorization for Kisunla, an Alzheimer’s treatment developed by the pharmaceutical giant. This decision marks a notable blow to Lilly's ambitions within the neurodegenerative disease space, as Kisunla was being heralded as a promising solution for individuals battling Alzheimer’s.
Continue reading
Eli Lilly Reports Full-Year Profit Outlook Amid Recent Earnings Misses
In a recent financial update, Eli Lilly and Company has provided its projections for the full year, revealing that its expected profit aligns with analysts' forecasts despite experiencing setbacks in some of its recent earnings reports. The pharmaceutical giant has faced challenges but remains optimistic as it leverages its strong portfolio of drugs.
Continue reading
Lilly's 2024 Sales Figures Fall Short Amidst Weaker Weight Loss Drug Demand
In a significant update from Eli Lilly and Company, the pharmaceutical giant revealed that its sales for 2024 did not meet expected projections. The company's performance was primarily impacted by a noticeable slowdown in the revenue generated by its popular weight-loss medications, a sector that has recently garnered immense attention and demand.
Continue reading
Lilly Urges Biden Administration to Halt Drug Price Negotiations
In a surprising turn of events, Eli Lilly, a major player in the pharmaceutical industry, has formally requested that the Biden administration place a pause on the ongoing negotiations regarding drug pricing. This request comes amidst growing concerns and efforts from various pharmaceutical firms regarding the impact of recent legislative changes on their operations and profitability.
Continue reading
Lilly Commits Up to $2.5 Billion for Scorpion's Groundbreaking Cancer Treatment
In a significant move within the pharmaceutical realm, Eli Lilly and Company has announced an agreement to purchase Scorpion Therapeutics’ innovative cancer therapy. The deal, potentially valued at an astonishing $2.5 billion, underscores Lilly's strategic push to enhance its oncology portfolio amidst a fiercely competitive market. This acquisition comes at a time when companies are aggressively seeking novel treatments to address the growing demands of cancer patients globally.
Continue reading
Lilly's Zepbound Breaks Ground with First U.S. Drug Approval for Sleep Apnea
In a groundbreaking development for the treatment of sleep apnea, Eli Lilly and Company has secured its first drug approval with Zepbound, marking a significant milestone in the pharmaceutical landscape for addressing this common sleep disorder. This approval not only opens doors for more effective interventions but also raises hopes for millions suffering from the condition across the United States.
Continue reading